Type 2 & other diabetes

High blood glucose index stratifies glycaemic severity and identifies occult type 2 diabetes risk in prediabetes via single‐day continuous glucose monitoring: A multi‐cohort study

Diabet MedPublished Multi-cohort study

Authors' conclusion

HBGI is a device-agnostic metric that effectively stratifies glycaemic severity. A single-day HBGI assessment provides complementary risk stratification by unmasking occult risk in prediabetes with established CGM indices within recommended ranges.

Study context

Population
Healthy individuals and individuals with prediabetes or diabetes with continuous glucose monitoring (CGM) records365 valid CGM records
Exposure
High Blood Glucose Index (HBGI) vs other CGM indices for predicting progression to T2D
Outcome
Platform-independent robustness of CGM-derived HBGI and predictive utility of a single day for progression to T2D
Methodological detailsthree CGM devices, four independent cohorts, cross-sectional and longitudinal analyses
  • Three CGM devices
  • Four independent cohorts
  • Cross-sectional and longitudinal analyses

Main finding

As reported in the abstract

HBGI variance, gradient across glycaemic stages and prediction of progression
Share of total HBGI variance explained by device type
3.4%
Share of total HBGI variance explained by metabolic status
31.8%
Stepwise increase in HBGI from healthy through prediabetes to diabetes (cross-sectional)
p < 0.001
Baseline HBGI differentiated progressors from non-progressors
p = 0.005
AUC of single-day baseline HBGI for progression
0.74 (95% CI 0.61-0.85)

Observational data: associations, not effects.

Further findings

Progression risk in prediabetes with established glycaemic indices within recommended ranges, by elevated HBGI (>0.174)

Elevated HBGI identified an occult high-risk subgroup; fold-higher progression risk
5.39- to 6.13-fold

Original publication

High blood glucose index stratifies glycaemic severity and identifies occult type 2 diabetes risk in prediabetes via single‐day continuous glucose monitoring: A multi‐cohort study. Diabet Med. Published 13 August 2026. doi:10.1111/dme.70437

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.